行情

ACOR

ACOR

阿索尔达治疗
NASDAQ

实时行情|Nasdaq Last Sale

3.490
+0.100
+2.95%
盘后: 3.490 0 0.00% 16:45 09/20 EDT
开盘
3.390
昨收
3.390
最高
3.580
最低
3.340
成交量
520.10万
成交额
--
52周最高
21.63
52周最低
2.270
市值
1.68亿
市盈率(TTM)
-1.7600
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACOR 新闻

  • Acceleron Discontinues Mid-Stage Muscular Dystrophy Study
  • Zacks.4天前
  • Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%
  • Zacks.com.4天前
  • Acorda to Present Data at the International Congress of Parkinsons Disease and Movement Disorders
  • Business Wire.4天前
  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
  • Zacks.6天前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ACOR 简况

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
展开

Webull提供Acorda Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。